4//SEC Filing
Campbell David Alan 4
Accession 0001415889-24-024074
CIK 0001817713other
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 7:30 PM ET
Size
9.0 KB
Accession
0001415889-24-024074
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-09-27$46.09/sh−18,957$873,715→ 313,097 total - Sale
Common Stock
2024-09-27$46.85/sh−5,248$245,895→ 307,849 total - Sale
Common Stock
2024-09-27$47.84/sh−795$38,032→ 307,054 total
Footnotes (4)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
- [F2]The weighted average sale price for the transaction reported was $46.0893 and the range of prices were between $45.55 and $46.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $46.855 and the range of prices were between $46.565 and $47.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $47.8384 and the range of prices were between $47.56 and $48.135. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0001864158
Filing Metadata
- Form type
- 4
- Filed
- Sep 26, 8:00 PM ET
- Accepted
- Sep 27, 7:30 PM ET
- Size
- 9.0 KB